Global Neurology Academy - Global Neurology Academy

Global Neurology Academy

Global Neurology Academy

Enhance your practice with CME
and tools that focus on the management
of neurological conditions.

Popular

Understanding Variability in Myasthenia Gravis
Understanding Variability in Myasthenia Gravis
NeuroFrontiers
Understanding Variability in Myasthenia Gravis
Henry Kaminski, MD
- Henry Kaminski, MD
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
CME/CE Broadcast Replay
Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments
Prem S. Subramanian, MD, PhD; Andrew G. Lee, MD
1.00 credit
- Prem S. Subramanian, MD, PhD
- Andrew G. Lee, MD
- Valerie Biousse, MD
1.00 credit
Tau Therapies and Clinical Translation: Mechanistic Approaches
Tau Therapies and Clinical Translation: Mechanistic Approaches
MinuteCE®
Tau Therapies and Clinical Translation: Mechanistic Approaches
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
MinuteCE®
Beyond Cognition: Managing Alzheimer’s as an Integrated Neurodegenerative–Neuropsychiatric Syndrome
Dani Cabral, MD; Marwan Sabbagh, MD, FAAN
0.75 credits 6 episodes
- Dani Cabral, MD
- Marwan Sabbagh, MD, FAAN
0.75 credits 6 episodes
CME/CE In-Person Event
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026
Chicago, Illinois
1.50 credits
NPS Agitation: Evidence and Emerging Mechanisms of Management
NPS Agitation: Evidence and Emerging Mechanisms of Management
MinuteCE®
NPS Agitation: Evidence and Emerging Mechanisms of Management
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
NeuroFrontiers
Microglia Drive Neurodegeneration in Friedreich’s Ataxia
Ryan Quigley
- Ryan Quigley
Unpacking the Genetics of Friedreich’s Ataxia
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiers
Unpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
- Arnulf Koeppen, MD

Medical News

Medical News
Inebilizumab vs Low-Dose Rituximab In NMOSD
05/05/2026
Read more
Medical News
Season Timing and Concussion Outcomes in Division I Football
05/04/2026
Read more
Medical News
Exercise and Nicotinamide Riboside in Friedreich's Ataxia: Trial Results
05/01/2026
Read more
Medical News
LiSN-S Testing and Auditory Dysfunction in Friedreich's Ataxia
05/01/2026
Read more

CME/CE

Amyloid-β Therapies in Practice: Not All Are Created Equal
Amyloid-β Therapies in Practice: Not All Are Created Equal
MinuteCE®
Amyloid-β Therapies in Practice: Not All Are Created Equal
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
Neuroinflammation to Network Instability: Translating FAAH/MAGL Biology to NPS
Neuroinflammation to Network Instability: Translating FAAH/MAGL Biology to NPS
MinuteCE®
Neuroinflammation to Network Instability: Translating FAAH/MAGL Biology to NPS
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
Unseen Impact of NPS in AD: Domains and Burden
Unseen Impact of NPS in AD: Domains and Burden
MinuteCE®
Unseen Impact of NPS in AD: Domains and Burden
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits
NPS Psychosis: Circuits, Treatment, and New Hope
NPS Psychosis: Circuits, Treatment, and New Hope
MinuteCE®
NPS Psychosis: Circuits, Treatment, and New Hope
Dani Cabral, MD; Mohammed Q. Al-Sabbagh, MD
0.75 program credits
- Dani Cabral, MD
- Mohammed Q. Al-Sabbagh, MD
0.75 program credits

Clinical Practice

Examining the Global Genetic Prevalence of TK2d
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiers
Examining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP; Austin Larson, MD
- Brian P. McDonough, MD, FAAFP
- Austin Larson, MD
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
CME/CE Virtual Event
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
June 15, 2026
07:30 AM - 09:00 AM ET
1.50 credits
Is Friedreich’s Ataxia Developmental or Degenerative?
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiers
Is Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiers
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG

Programs

FXIa Remix! Keeping the Flow Without Missing a Beat
FXIa Remix! Keeping the Flow Without Missing a Beat
CME/CE
FXIa Remix! Keeping the Flow Without Missing a Beat
Mike Sharma, MD, MSc, FRCPC; Ashkan Shoamanesh, MD
0.50 credits
- Mike Sharma, MD, MSc, FRCPC
- Ashkan Shoamanesh, MD
- Brian Mac Grory, MB, BCh BAO, MRCP, FAHA, FANA
0.50 credits
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiers
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
NeuroFrontiers
Next-Generation MS Care: The Promise of Cell-Based Therapeutics
Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
- Mark Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals
NeuroFrontiers
Omaveloxolone in Friedreich’s Ataxia: Early Real-World Signals